Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals' Total Non-Current Liabilities history spans 14 years, with the latest figure at $152.2 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 40.86% to $152.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $152.2 million, a 40.86% increase, with the full-year FY2025 number at $152.2 million, up 40.86% from a year prior.
  • Total Non-Current Liabilities hit $152.2 million in Q4 2025 for Vanda Pharmaceuticals, up from $124.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VNDA hit a ceiling of $152.2 million in Q4 2025 and a floor of $72.9 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $101.3 million across 5 years, with a median of $99.8 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 9.08% in 2023 and later surged 40.86% in 2025.
  • Tracing VNDA's Total Non-Current Liabilities over 5 years: stood at $84.5 million in 2021, then increased by 18.67% to $100.2 million in 2022, then dropped by 5.53% to $94.7 million in 2023, then increased by 14.12% to $108.1 million in 2024, then skyrocketed by 40.86% to $152.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for VNDA at $152.2 million in Q4 2025, $124.1 million in Q3 2025, and $128.4 million in Q2 2025.